DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension

Information source: Takeda
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Candesartan cilexetil and hydrochlorothiazide (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Takeda

Official(s) and/or principal investigator(s):
Medical Director, Study Director, Affiliation: Takeda Pharma GmbH (Germany)

Summary

The purpose of this study is to see if Candesartan, once daily (QD), added with Hydrochlorothiazide may be helpful in treating people with newly diagnosed severe essential hypertension.

Clinical Details

Official title: Clinical Study to Evaluate the Efficacy and Safety of the Combination Therapy Candesartan Cilexetil 32 mg Plus Hydrochlorothiazide 25 mg in Patients With Severe Hypertension

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Change from Baseline in Systolic Blood Pressure at Week 9.

Change from Baseline in Diastolic Blood Pressure at Week 9.

Secondary outcome:

Percentage of subjects showing a decrease in SBP to less than 140 mmHg and/or a decrease of SBP by at least 20 mmHg AND a decrease in DBP to less than 90 mmHg and/or a decrease of DBP by at least 10 mmHg.

Percentage of subjects showing a decrease in SBP to less than 130 mmHg and/or a decrease of SBP by at least 20 mmHg AND a decrease in DBP to less than 80 mmHg and/or a decrease of DBP by at least 10 mmHg.

Change from Baseline in Pulse Rate at Week 9.

Change from Baseline in Systolic Blood Pressure at Final Visit.

Change in Baseline in Diastolic Blood Pressure at Final Visit.

Change from Baseline in Pulse Rate at Final Visit.

Detailed description: Medical data show a link between blood pressure and the risk of heart disease (cardiovascular disease) such as stroke and heart attack. Clinical trials have shown that lowering blood pressure in patients with high blood pressure (hypertension) reduces the number of cardiovascular events. Many people still have untreated hypertension. There are many reasons why target blood pressure is not reached. One is that most patients need more than one antihypertensive drug in order to lower high blood pressure. Other reasons include poor patient compliance with taking their drugs. Combining drugs that lower high blood pressure and have similar ways of working in the body may help high blood pressure and lower the risk for medication-related side effects. One of several drug combinations recommended for the treatment of high blood pressure is an angiotensin receptor blocker and a thiazide diuretic. Guidelines also note that combination tablets may improve patient compliance with taking their drugs. Candesartan is an angiotensin type-1 receptor blocker. Hydrochlorothiazide is a diuretic with blood pressure-lowering effect. This study will combine both of these drugs in one pill and see how it works in people taking part in this study.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Confirmed diagnosis of essential hypertension.

- Has Systolic Blood Pressure between 150 mmHg and 200 mmHg AND Diastolic Blood

Pressure between 110 mmHg and 120 mmHg.

- Has not received any antihypertensive treatment so far.

- Has a negative pregnancy test at baseline in females of childbearing potential. Male

and female participants with reproductive potential must use an approved contraceptive method during study treatment evaluation Exclusion Criteria:

- Has a known or suspected secondary hypertension or primary hyperaldosteronism.

- Has impaired renal function.

- Has severe hepatic impairment.

- Has bilateral renal artery stenosis, solitary kidney or post-renal transplant status.

- Has a history of myocardial infarction, coronary artery bypass graft, percutaneous

coronary intervention or cerebral accident (stroke or transient ischaemic attack) within the last 6 months.

- Has a diagnosis or suspicion of the following conditions: hypertrophic obstructive

cardiomyopathy, angina pectoris, chronic heart failure, peripheral arterial occlusive disease, hypertensive retinopathy.

- Has hemodynamically relevant stenosis of the aortic or mitral valve.

- Has clinically relevant and refractory hypokalaemia or hyperkalaemia.

- Has uncorrected volume or sodium depletion.

- Has gout or relevant hyperuricaemia.

- Has a known intolerance/hypersensitivity to Candesartan cilexetil or

Hydrochlorothiazide.

- Has a known galactose intolerance, lactase deficiency or glucose-galactose

malabsorption.

- Is taking psychotropic medication or is addicted to alcohol or drugs.

- Has participated in another trial of an investigational drug or a medical device

within the last 30 days or is currently participating in another trial of an investigational drug or a medical device.

Locations and Contacts

Berlin, Germany

Blankenhain, Germany

Dortmund, Germany

Hamburg, Germany

Köthen, Germany

Löhne, Germany

Nürnberg, Germany

Remscheid, Germany

Rodgau, Germany

Stockach, Germany

Wardenburg, Germany

Weinheim, Germany

Ivano-Frankivsk, Ukraine

Kharkiv, Ukraine

Kiev, Ukraine

Lviv, Ukraine

Additional Information

Starting date: October 2009
Last updated: July 12, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017